[Antitumor effects and clinical problems of transcatheter intraarterial infusion for uterine cervical cancer].

Abstract

Several studies have confirmed that neoadjuvant chemotherapy and concurrent chemoradiation improved survival compared with standard therapy for uterine cervical cancer. There have been many reports on the use of transcatheter intraarterial infusion (TAI) with anticancer drugs, but there are no randomized controlled trials in Japan. Our study of transcatheter arterial infusion before operation or radiotherapy for uterine cervical cancer was performed for 49 patients,and the number of patients with stage Ib (bulky tumor>3 cm), II, III, or IVa disease were 15, 18, 11, and 5, respectively. The drugs infused were cisplatin (100 mg/m(2)) or carboplatin (300 mg/m(2)). The median survival time, 2-and 5-year survival rates were 62 months, 81.6%, and 70.6%, respectively. There were no grade 4 acute toxicities. As a late complication, ileus occurred in 8.2%. TAI may improve the prognosis of patients who underwent a radical operation after TAI.

• Authors: Kazuhisa Fujiwara
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 33 Issue 9 Pg. 1236-40 (Sep 2006) ISSN: 0385-0684 [Print] Japan
• PMID: 16969017 (Publication Type: English Abstract, Journal Article)

Chemical References

• Carboplatin
• Cisplatin

Topics

• Adenocarcinoma (drug therapy, mortality, pathology)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Carboplatin (administration & dosage)
• Carcinoma, Adenosquamous (drug therapy, mortality, pathology)
• Carcinoma, Squamous Cell (drug therapy, mortality, pathology)
• Cisplatin (administration & dosage)
• Female
• Humans
• Ileus (etiology)
• Infusions, Intra-Arterial (methods)
• Leukopenia (chemically induced)
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Staging
• Prognosis
• Survival Rate
• Uterine Cervical Neoplasms (drug therapy, mortality, pathology)